ncRNAs are moving from molecular curiosity to therapeutic leverage in cancer immunity

Cancer behavior is not determined by malignant cells alone. The tumor microenvironment, immune exclusion, stromal remodeling, hypoxia, and acidosis all shape whether immune cells can attack or are instead pushed toward dysfunction and tolerance. This editorial places non-coding RNAs at the center of that biology, arguing that miRNAs, lncRNAs, circRNAs, and related species help script the immune states that decide whether a tumor responds to treatment or slips into resistance.

The framing is clinically important because cancer immunotherapy still fails too often. Even when checkpoint blockade, cell therapy, chemotherapy, or radiation is deployed with precision, response rates remain uneven across patients and tumor types. ncRNAs offer one explanation for that variability: they influence immune-cell differentiation, activation, antigen presentation, cytokine signaling, macrophage polarization, T-cell function, and the communication loops that allow tumors to evade immune pressure.

One sentence captures the core message of the issue: immune escape is often written into the transcriptome before it is visible at the bedside.

The most concrete translational signal comes from the colorectal cancer study in the Research Topic. Using single-cell transcriptomic analyses alongside bulk gene expression data from NK cells, investigators built a 16-lncRNA risk model that predicted mortality and validated it in independent clinical samples. They also proposed four colorectal cancer microenvironment subtypes based on NK cell-derived lncRNA profiles, suggesting that the NK compartment is not a uniform bystander population but a biologically stratified arm of antitumor immunity.

The functional data sharpen that point. lncRNA AC010319.3 reduced NK cell activity, identifying a candidate molecule that may blunt innate immune surveillance. In practical terms, this type of result matters because NK-cell exhaustion or suppression can leave tumor clearance dependent on adaptive immunity alone, narrowing the window for effective immune control. The study also illustrates how ncRNA signatures may serve two purposes at once: they can act as prognostic classifiers and as mechanistic clues pointing toward therapeutic targets.

For colorectal cancer, the larger implication is not just that a single lncRNA matters. It is that the immune microenvironment may be partitioned into molecular subtypes that behave differently under treatment pressure, which could help explain why some patients respond while others do not.

Testicular germ cell tumors expose a gap between biomarker promise and functional proof

In testicular germ cell tumors, the editorial turns to miRNAs and immunotherapy in a setting where advanced, relapsed, or treatment-refractory disease still creates unmet clinical need. The review connects miRNAs with checkpoint signaling, antigen presentation, cytokine programs, macrophage polarization, dendritic cell function, T-cell activity, and tumor-immune communication through extracellular vesicles. It also treats miRNAs as potential biomarkers of immunotherapy sensitivity or resistance.

The caution is straightforward. Much of the proposed immunoregulatory biology remains supported by limited TGCT-specific functional evidence. That gap is not trivial. A biomarker that looks persuasive in association studies can fail when tested in the immune complexity of human tumors, especially when the same small RNA can affect multiple cell types and pathways simultaneously. For TGCT, the review makes a measured case: miRNAs are biologically plausible regulators, but clinical translation still depends on tissue-specific validation and mechanistic confirmation.

CircRNA immunotherapy in esophageal cancer faces an attribution problem

The perspective on esophageal squamous cell carcinoma is unusually methodologic and highly relevant to translational work. It describes an “attribution gap” in circRNA immunotherapy research, where three forces can all shape the same experimental readouts: the intrinsic immunogenicity of exogenous circRNA, the abundance of endogenous tumor circRNA, and the patient’s baseline interferon state. All three can influence interferon output, protein yield, and immune phenotypes, which makes dose-response interpretation less straightforward than it appears.

The consequence reaches beyond technical debate. If investigators cannot separate source effects from response effects, therapeutic optimization becomes uncertain and risk stratification weakens. Measuring these variables concurrently from the design stage and pairing association analysis with causal inference may be the only way to identify which signal belongs to the delivered construct and which belongs to the host tumor-immune environment.

The liver cancer review extends the same ncRNA logic into hepatitis B virus-related hepatocellular carcinoma. HBx dysregulates ncRNAs and alters pathways such as Wnt/β-catenin, PI3K/AKT, TGF-β, and MAPK, all of which can influence proliferation, apoptosis, epithelial-mesenchymal transition, and angiogenesis. ncRNAs are therefore presented not just as passive markers of disease state but as active mediators of oncogenic reprogramming. Delivery problems and limited validation remain the major barriers to translation.

In gastric cancer, ncRNAs are tied to immune-cell infiltration, checkpoint control, immunosuppression, and epigenetic reprogramming. The review also considers them as liquid biopsy biomarkers and as potential partners to checkpoint inhibitors, CAR-T therapy, chemotherapy, and radiotherapy. The mechanistic logic is familiar but clinically relevant: tumors do not resist therapy through one pathway alone. They recruit networks of RNA-mediated changes that can dampen immune recognition, alter stromal interactions, and blunt cytotoxic killing.

FOSL1 sits inside a broader ncRNA network of metastasis and immune evasion

The final review places FOSL1 in a bidirectional regulatory network with miRNAs, lncRNAs, circRNAs, and piRNAs across several cancers. The shared theme is immune evasion and therapy resistance, including regulation of tumor-associated macrophages and the FOSL1–PD-L1 axis. This matters because immune escape often emerges from intersecting regulatory loops rather than a single switch. FOSL1 may function as one of the nodes that helps coordinate those loops across tumors with different origins.

Across the six articles, the editorial reaches a restrained but clear conclusion. ncRNAs have credible potential as biomarkers for stratification and as therapeutic targets for reshaping antitumor immunity. The same editorial also makes the barriers plain: incomplete functional characterization, off-target effects, tumor heterogeneity, and delivery constraints continue to slow clinical movement. Future progress will depend on independent validation, single-cell and multi-omic methods, and delivery systems that can reach the right immune or tumor compartment without broad collateral effects.

The field is close to useful biology and still far from routine translation. For now, the most defensible claim is narrower: ncRNAs are already altering how investigators understand immune resistance in cancer, but the path from molecular mechanism to therapy remains contingent on rigorous functional proof and clinically anchored validation.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA